Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-dose teniposide for refractory malignancies: a phase I study.

E G de Vries, N H Mulder, P E Postmus

    Cancer Treatment Reports
    |May 1, 1986
    PubMed
    Summary

    This phase I study evaluated teniposide (VM-26) toxicity, finding severe skin rash and dose-dependent leukocytopenia/thrombocytopenia at higher doses. Further research at 0.6 g/m2 is recommended for phase II trials.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Early development of the metabolic syndrome after chemotherapy for testicular cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2012
    Same author

    Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors.

    Annals of oncology : official journal of the European Society for Medical Oncology·2009
    Same author

    111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.

    European journal of cancer (Oxford, England : 1990)·2007
    Same author

    Quality of life of testicular cancer survivors and the relationship with sociodemographics, cancer-related variables, and life events.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2005
    Same author

    Use of natriuretic peptides for detecting cardiac dysfunction in long-term disease-free breast cancer survivors.

    Anticancer research·2005
    Same author

    Left ventricular and cardiac autonomic function in survivors of testicular cancer.

    European journal of clinical investigation·2005

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Teniposide (VM-26) is a semisynthetic podophyllotoxin derivative.
    • Phase I studies are crucial for evaluating novel chemotherapeutic agents.

    Purpose of the Study:

    • To determine the dose-limiting toxicity of teniposide (VM-26).
    • To establish a safe and potentially effective dose for future clinical trials.

    Main Methods:

    • A phase I clinical trial was conducted.
    • Teniposide (VM-26) was administered over 3 consecutive days.
    • Dose escalation from 0.3 g/m2 to 0.6 g/m2 and 1 g/m2 was performed.

    Main Results:

    • Severe skin rash occurred in all patients at the highest dose (1 g/m2).
    • Dose-dependent leukocytopenia and thrombocytopenia were observed, with severe reductions at 1 g/m2.

    Related Experiment Videos

  • Partial remission was seen in 5/13 patients, with 1 minor response and 4 stable disease cases.

    • Conclusions:

    • The dose-limiting toxicities of teniposide (VM-26) include severe skin rash and myelosuppression.
    • A dose of 0.6 g/m2 is suggested for further phase II studies in specific tumor types.